Estrogen receptor α gene PvuII polymorphism and coronary artery disease: a meta-analysis of 21 studies

Ding, Jie; Xu, Hui; Yin, Xiaoxing; Zhang, Furong; Pan, Xiaoping; Gu, Yian; Chen, Jun-zhu; Guo, Xiaogang

doi:10.1631/jzus.b1300220

Cited by 19 publications

(24 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mechanisms by which coexistence of CAD and ARAS is associated with HFpEF are under investigation (Groban and Kitzman, 2010;Wang and Shi, 2014). The progressive increase in cardiac diastolic dysfunction leading to a worsening of CAD and ARAS is partly explained by factors such as increased afterload, renal hypertension resulting from ARAS, myocardial ischemia, overactivation of RAAS, and inflammation (Ding et al, 2014). Risks that increase with coexisting CAD and ARAS complicated by HFpEF include oxidative stress, de-arrangements in calcium-phosphate homeostasis, and conditions promoting coagulation, all of which share similar pathogenic factors associated with accelerated atherosclerosis and endothelial dysfunction (de Silva et al, 2005;Liu et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease

Dong

Huang

Luo

et al. 2016

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Percutaneous transluminal renal artery stenting (PTRAS) has been proved to have no more benefit than medication alone in treating atherosclerotic renal artery stenosis (ARAS). Whether PTRAS could improve left ventricular hypertrophy (LVH) and reduce adverse events when based on percutaneous coronary intervention (PCI) for patients with coronary artery disease (CAD) and ARAS is still unclear. A retrospective study was conducted, which explored the effect of concomitant PCI and PTRAS versus PCI alone for patients with CAD and ARAS complicated by heart failure with preserved ejection fraction (HFpEF). A total of 228 patients meeting inclusion criteria were divided into two groups: (1) the HFpEF-I group, with PCI and PTRAS; (2) the HFpEF-II group, with PCI alone. Both groups had a two-year follow-up. The left ventricular mass index (LVMI) and other clinical characteristics were compared between groups. During the follow-up period, a substantial decrease in systolic blood pressure (SBP) was observed in the HFpEF-I group, but not in the HFpEF-II group. There was marked decrease in LVMI in both groups, but the HFpEF-I group showed a greater decrease than the HFpEF-II group. Regression analysis demonstrated that PTRAS was significantly associated with LVMI reduction and fewer adverse events after adjusting for other factors. In HFpEF patients with both CAD and ARAS, concomitant PCI and PTRAS can improve LVH and decrease the incidence of adverse events more than PCI alone. This study highlights the beneficial effect of ARAS revascularization, as a new and more aggressive revascularization strategy for such high-risk patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease

Dong

Huang

Luo

et al. 2016

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

Section: Oestrogen Receptors -Division and Role In The Female Bodymentioning

confidence: 99%

“…In many studies, a relationship was confirmed between PvuII polymorphism carrier state and many abnormalities [7], such as: breast cancer [10], atherogenic lipid profile changes, hypertension, and coronary atherosclerosis [25]. A controversial issue in many studies is the relationship between PvuII polymorphism and the risk of development of ischaemic heart disease (IHD) [7].…”

Section: Consequences Of Oestrogen Deficiency and Oestrogen Receptor mentioning

confidence: 99%

“…Oestrogen receptors are present in the hypothalamus, olfactory lobe, amygdala, hippocampus, cerebral cortex, cerebellum, pituitary gland, bone tissue (osteoblasts and osteoclasts), the cardiovascular system, and the liver. A high ERa expression was observed in: endometrial glandular epithelium, mammary glands, pituitary gland, adrenal glands, endothelium, and vascular smooth muscle (ERa plays a more important role in cardioprotection than ERb, considering the participation in vasodilatation, neovascularisation, and weakening cell apoptosis in the cardiac muscle [7]), as well as the liver and testis.However, a high ERb expression was found in the kidneys, gastric and duodenal mucosa, small intestine, colon, rectum, lungs, spleen, peripheral blood leukocytes, bone marrow, prostate, urinary bladder, and ovary: in granular cells, in the cells of areola and in the corpus luteum. The ERa expression in ovarian granular cells is considerably lower, but it does not occur at all in the thecal cells.…”

mentioning

confidence: 99%

“…The results of recent studies indicate that there is a relationship between genotypes Xba1 AA and PvuII CC, and an increased risk of osteoporosis in the Asian population, while among the Caucasian population an increased risk of osteoporosis is associated with genotypes Xba1 AA and PvuII TT [24]. In addition, the prevalence of haplotype CA is typical of Asian, compared to the Caucasian population.In many studies, a relationship was confirmed between PvuII polymorphism carrier state and many abnormalities [7], such as: breast cancer [10], atherogenic lipid profile changes, hypertension, and coronary atherosclerosis [25]. A controversial issue in many studies is the relationship between PvuII polymorphism and the risk of development of ischaemic heart disease (IHD) [7].…”

mentioning

confidence: 99%

See 2 more Smart Citations

The polymorphism of estrogen receptor α is important for metabolic consequences associated with menopause

Pinkas

Gujski

Wierzbińska-Stępniak

et al. 2016

Endokrynologia Polska

View full text Add to dashboard Cite

The menopause is associated with multiple health and metabolic consequences resulting from the decrease in oestrogen levels. Women at postmenopausal age are burdened with a higher risk of cardiovascular diseases, and the main cause of mortality in this group is ischaemic heart disease. Oestrogen deficiency is related, among other things, with frequent occurrence of dyslipidaemia, cessation of the beneficial effect of oestrogens on the vascular wall, and increase in body weight characterised by unfavourable redistribution of fatty tissue, with an increased amount of visceral fat and reduction of so-called non-fatty body mass. Oestrogens exert an effect on the metabolism, mainly through the genomic mechanism. The presence of a and b oestrogen receptors was found in many tissues and organs. Recently, attention has been paid to the fact that the effect of oestrogen action on tissues and organs may depend not only on their distribution, but also on their polymorphic types. This article presents the latest approach to the problem of metabolic consequences resulting from menopause, according to the possessed a oestrogen receptor polymorphism (ERa). Genes encoding for ERa have many polymorphic variants, the most important of which from the clinical aspect are two single nucleotide polymorphisms (SNPs): Xba1 and PvuII. The review of literature indicates that ERa polymorphisms are of great importance with respect to the effect of oestrogens on the functioning of the body of a woman after menopause, and may imply the development of many pathological states, including the prevention or development of metabolic disorders. Identifying ERa polymorphisms may be useful in oestrogen therapy for menopausal women who may benefit from it. (Endokrynol Pol 2016; 67 (6): 608-614) Key words: menopause; oestrogen receptor; metabolic disorders StreszczenieMenopauza związana jest z wieloma zdrowotnymi i metabolicznymi konsekwencjami wynikającymi ze spadku poziomu estrogenów. Kobiety w wieku pomenopauzalnym są obarczone wyższym ryzykiem chorób sercowo-naczyniowych, a główną przyczyną śmiertelności w tej grupie jest choroba niedokrwienna serca. Niedobór estrogenów związany jest między innymi z częstym występowaniem dyslipidemii, przerwaniem korzystnego oddziaływania estrogenów na ściany naczyń, zwiększeniem masy ciała charakteryzującym się niekorzystnym rozmieszczeniem tkanki tłuszczowej o zwiększonej ilości tłuszczu trzewnego i redukcji tak zwanej beztłuszczowej masy ciała. Estrogeny wywierają wpływ na metabolizm głównie poprzez mechanizm genomowy. Obecność receptorów estrogenowych a i b została stwierdzona w wielu tkankach i narządach. Ostatnio zwrócono uwagę na fakt, że efekt działania estrogenów na tkanki i narządy może zależeć nie tylko od rozkładu, ale również od rodzaju ich typów polimorficznych. W artykule przedstawiono najnowsze podejście do problemu metabolicznych następstw wynikających z menopauzy, w zależności od posiadanego polimorfizmu receptora estrogenowego alfa (ERa). Geny kodujące ERa mają wiele wariantów polimorfic...

show abstract

Considering the Pathogenesis of Atherosclerosis to Explain CIMT-But Not CAC-Proven Estrogen Atheroprevention in the Elite Trial

Friedenthal

Naftolin

2018

Reproductive Medicine for Clinical Practice

View full text Add to dashboard Cite

Estrogen receptor α gene PvuII polymorphism and coronary artery disease: a meta-analysis of 21 studies

Cited by 19 publications

References 49 publications

Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease

Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease

The polymorphism of estrogen receptor α is important for metabolic consequences associated with menopause

Considering the Pathogenesis of Atherosclerosis to Explain CIMT-But Not CAC-Proven Estrogen Atheroprevention in the Elite Trial

Contact Info

Product

Resources

About